Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Employer Implications As oral nonpeptide GLP1s and combination therapies approach market entry, plan sponsors should anticipate expanded utilization, increased clinical complexity and heightened pressure on costcontainment strategies
Semaglutide was FDA-approved to treat obesity in 2021
Severe metabolic and endocrine disturbances such as hypocalcemia, hypomagnesemia, hypoglycemia, hypothyroidism, and uroparesis, can also occur in a small number of patients [24, 26]
Again, this link is mostly driven by weight people with obesity are far more likely to have sleep apnea, and losing weight is linked to an improvement in symptoms
At Physicians Plan, we understand how difficult losing weight can be for some people, which is why we offer treatments designed specifically for those who need them most
95% CI, -13.4 to -11.5
